We report a 6-year-old boy with SAVI carrying the TMEM173 p.N154S mutation who failed multiple JAK inhibitors, including ruxolitinib, tofacitinib, and baricitinib and developed worsening lung fibrosis and cutaneous ulcers. This evidence concerns the gene STING1 and STING-associated vasculopathy with onset in infancy.